Teva's CGRP Migraine Med Hits a Stumbling Block Post author:Sam Post published:February 8, 2018 Post category:BioPharma It’s starting to feel like Teva can’t catch a break. Source: BioSpace You Might Also Like Denali Top Exec Jumps Ship for Bay Area Anti-Aging Startup Alkahest January 22, 2018 Rhythm's IPO Exceeds Expections, Raises $120 Million In Debut October 4, 2017 EpimAb Biotherapeutics Raises $25M In Series A Financing From International Consortium To Advance Pipeline Of Novel Bispecific Antibodies April 24, 2017
EpimAb Biotherapeutics Raises $25M In Series A Financing From International Consortium To Advance Pipeline Of Novel Bispecific Antibodies April 24, 2017
